Sirona Biochem Corp V.SBM

Alternate Symbol(s): SRBCF

Healthcare Biotechnology

Sirona Biochem Corp. is a cosmetic ingredient and drug discovery company with a proprietary technology platform developed at its laboratory facility in France with a specialization in the stabilization of carbohydrate molecules. The Company is exploring the areas of diabetes, dyschromia, anti-aging, anti-cellulite and antiviral therapies and relies on a business model of licensing patents to large organizations in return for up-front and milestone payments as well as royalties. Its two most advanced programs are the cosmetic skin lightener and diabetes drug. The Company's TFC-1067 is for the treatment of Dyschromia (Dark spots on the skin). GlycoProteMim is a novel anti-aging compound. GlycoProteMim is based on the naturally occurring glycoproteins found in Antarctic fish, known to protect them against environmental stressors. It is focused on three current antiviral categories: Neuraminidase Inhibitors, Nucleoside Analogs and Iminosugars. Its wholly owned subsidiary is TFChem S.A.R.L.

TSXV:SBM - Post by User

Sirona Biochem Corp > June presentation

<< Previous

Bullboard Posts

Next >>

Post by biorunon Jun 01, 2021 6:33pm

233 Views

Post# 33308004

June presentation

Its posted.

One of the German posters (Tenibrother) pointed out a subtle but potential telling difference between the May and June presentation. I don't have the May presentation so if someone does, please double validate and tell us. If so, this was a good catch. Lets see if the market places any value on this tomorrow am at opening.

here is the google translation:

"TFC-039 is currently in multiple Phase I clinical trials and expected to complete in the first half of 2021

What is striking compared to the May presentation is the underlining.
Now everyone can decide for themselves whether this can happen during the revision / update. I think that was done consciously.
That would be the end of this month."